Protein kinase C-β gene variants, pathway activation, and enzastaurin activity in lung cancer

Clinical Lung Cancer

Volumn 11, Issue 3, 2010, Pages 169-175

  Lee, Sang Haak ^a   Chen, Tingan ^b   Zhou, Jun ^b   Hofmann, Jennifer ^c   Bepler, Gerold ^b  

^a The Catholic University of Korea   (South Korea)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Akt; Drug activity; LY317615; Predictive marker; Sequence variants

Indexed keywords

ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 2; PROTEIN S6; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXON; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77952483027     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.021     Document Type: Article

References (21)

1. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-294
2. Barr L, Campbell S, Baylin S. Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ 1997;8:381-392
3. Murray NR, Davidson LA, Chapkin RS, et al. Overexpression of protein kinase C-beta 2 induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
4. Clark A, West K, Blumberg P, et al. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC-delta promotes cellular survival and chemo-therapeutic resistance. Cancer Res 2003;63:780-786
5. Partovian C, Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase C-alpha in endothelial cells. Cell Signal 2004;16:951-957
6. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C-beta selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-7469
7. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:1878-1885
8. Tang J, He Q, Guo R, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-191
9. Oh Y, Herbst RS, Burris H, et al. Enzastaurin, and oral serine/threonine inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008; 26:1135-1141
10. American Cancer Society. Cancer Facts and Figures, 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed: March 25, 2010.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
12. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
13. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568
14. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449
15. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolyl-maleimides: isozyme selective inhibitors of PKC-beta. Bioorg Med Chem Lett 2003;13:1857-1859
16. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls IkappaB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780-786
17. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2009; 27:416s.
18. Casey EM, Harb W, Bradford D, et al. Randomized, double blind, multicenter, phase II study of pemetrexed, carboplatin, bevacizumab with enzastaurin or placebo in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group (HOG) LUN06-116. Proc Am Soc Clin Oncol 2009; 27:415s.
19. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008; 99:2349-2355
20. Richards DA, Kuefler PR, Becerra C, et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs 2009; epub ahead of print.
21. Bodo J, Durkin L, Hsi ED. Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem 2009; 57:701-708